herpes zoster vaccine

Phase 2Vaccine

UUniversity of Alabama at Birmingham

herpes zoster vaccine is one of 69 biologic programs targeting Necrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NecrosisActive, not recruiting

Herpes ZosterActive, not recruiting

NecrosisPhase 2

Active, not recruiting

Herpes ZosterPreclinical

Active, not recruiting

Competition

Competitive Landscape

92 competitors in Herpes Zoster

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Phase 3

—2

Herpes Zoster Vaccine 1437173a

GSK

Phase 3

18 3

Rsvpref3 Vaccine

GSK

Phase 3

1 4

GSK 257049

GSK

Phase 3

1 5

Prevenar13

GSK

Phase 3

1 6

Boostrix

GSK

Phase 3

1 7

Valtrex

GGlaxo Dba Glaxosmithkline

Phase 2

4 8

Hz/su VACCINE

GSK

Phase 3

5 9

Valaciclovir

GSK

Phase 2

2 10

Influenza Vaccine

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Not yet recruiting

Herpes Zoster

NCT07170059

Clinical

Trials by Indication[1]

Herpes Zoster1 trial

Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients

Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University··NCT07170059·500 enrolled

Necrosis1 trial

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02538341·617 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for herpes zoster vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — herpes zoster vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for herpes zoster vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Alabama at Birmingham

herpes zoster vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Herpes Zoster1 trial

Necrosis1 trial

References

Drug Info

Quick Facts

Related News